|
1
|
Yu H, Wang H, Xu HR, Zhang YC, Yu XB, Wu MC, Jin GZ, Cong WM. Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence. Future Oncol 2019; 15:1771-1780. [PMID: 30997850 DOI: 10.2217/fon-2018-0606] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Aim: MTHFD1 was the enzyme providing one-carbon derivatives of tetrahydrofolate. We sought to investigate the impact of MTHFD1 on hepatocellular carcinoma (HCC). Methods: Bioinformatic analysis, western blot and immunohistochemistry were conducted to detect MTHFD1 expression in HCC. The relationships between MTHFD1 and prognosis of 172 HCCs were analyzed by Kaplan-Meier method and Cox proportional hazards model. Results: High MTHFD1 expression in HCC represented poor prognosis (overall survival p = 0.025; time to recurrence p = 0.044). Combining MTHFD1 with serum AFP, survival analysis demonstrated the prognosis of the MTHFD1 low expression and AFP ≤20 ng/ml group was better than that of the MTHFD1 high expression or AFP >20 ng/ml group and the MTHFD1 high expression and AFP >20 ng/ml group (overall survival p < 0.0001; time to recurrence p < 0.0001). Conclusion: High MTHFD1 expression in HCC indicated poorer prognosis. Combining MTHFD1 with serum AFP improved the accuracy of prognostic prediction.
Collapse
Affiliation(s)
- Hua Yu
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China.,Key Laboratory of Signaling Regulation & Targeting Therapy of Liver Cancer, The Second Military Medical University, Ministry of Education, Shanghai, 200438, PR China.,Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Han Wang
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China.,Key Laboratory of Signaling Regulation & Targeting Therapy of Liver Cancer, The Second Military Medical University, Ministry of Education, Shanghai, 200438, PR China.,Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Hai-Rong Xu
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Yu-Chan Zhang
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Xue-Bo Yu
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Meng-Chao Wu
- Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Guang-Zhi Jin
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China.,Key Laboratory of Signaling Regulation & Targeting Therapy of Liver Cancer, The Second Military Medical University, Ministry of Education, Shanghai, 200438, PR China.,Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| | - Wen-Ming Cong
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China.,Key Laboratory of Signaling Regulation & Targeting Therapy of Liver Cancer, The Second Military Medical University, Ministry of Education, Shanghai, 200438, PR China.,Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China
| |
Collapse
|